Experiences with

Lupkynis

However, eGFR didn’t decline as much in the Lupkynis group as it did in the placebo group. This meant that over the two years of AURORA 2, kidney function was protected in the Lupkynis group, but worsened in the placebo group.

A significantly greater proportion of Lupkynis-treated patients achieved CRR after a year of treatment (41%) compared with the placebo group (21.9%), with a nearly 2.5 times higher odds of achieving a response on Lupkynis.

“We are extremely pleased with the Swissmedic approval of Lupkynis for adults with lupus nephritis.

“The MHRA authorization of Lupkynis for individuals with lupus nephritis in Great Britain, on the heels of the marketing authorization in the EU, further expands the availability of Lupkynis as a treatment option for people with lupus nephritis,” said Peter Greenleaf, president and CEO of Aurinia, in

has generally had a better steroid-sparing profile than Lupkynis.

Lupkynis’ approval was supported by data from a Phase 3 trial called AURORA (NCT03021499). The study enrolled 358 adults ages 18–75 with active lupus nephritis. Participants were assigned randomly to take Lupkynis or a placebo for about one year.